The Danish drugmaker can expect lots of brand-new rivals in the Chinese market when its license for semaglutide ends in China following year.
发布者:BY PHILIP MADSEN,转转请注明出处:https://robotalks.cn/patent-expires-next-year-novo-nordisk-faces-tough-competition-in-the-chinese-obesity-market/